Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Website: bioatla.com


  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -151.3% (LTM)
  • Share price is 32.5% higher than minimum and 91.0% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (1.0x vs 0.0x)

Key Financials (Download financials)

Ticker: BCAB
Share price, USD:  (0.0%)0.3534
year average price 0.5085  


year start price 0.4646 2025-02-14

min close price 0.2667 2025-04-08

max close price 1.2200 2025-11-18

current price 0.3534 2026-02-13
Common stocks: 37 413 902

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):

Target EV / EBITDA (hist percentile): 0.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 13
Net Debt ($m): -214
EV (Enterprise Value): -201
EBITDA LTM (млн $): -202
Price to Book: -0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-12-31globenewswire.com

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

2025-11-21globenewswire.com

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

2025-11-13seekingalpha.com

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

2025-08-09seekingalpha.com

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

2025-01-02zacks.com

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

2024-11-09seekingalpha.com

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

2024-10-08seekingalpha.com

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

2024-10-07seekingalpha.com

BioAtla: Numerous Catalysts Coming In Q4

2024-10-04globenewswire.com

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

2024-10-01finbold.com

Michael Burry buys 634,000 shares of this $1 penny stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2023-11-07 2023-08-01 2023-05-11 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2025-03-27 17:44:56 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23 2022-02-28 16:25:51 2021-03-24 17:28:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 11M 11M 0 0 0 0 0 0 0 0 250 000 429 000
costOfRevenue 56 000 567 000 925 000 0 229 000 240 000 1M 270 000 290 000 0 1M 0 0 20M
grossProfit -56 000 -567 000 10M 11M -229 000 -240 000 -1M -270 000 -290 000 0 -1M 0 250 000 -20M
grossProfitRatio 0 0 1 0 0 0 0 0 0
researchAndDevelopmentExpenses 10M 14M 63M 16M 16M 19M 104M 28M 31M 22M 79M 20M 58M 20M
generalAndAdministrativeExpenses 0 5M 22M 6M 6M 6M 26M 7M 6M 7M 29M 6M 38M 11M
sellingAndMarketingExpenses 0 0 0 0 -229 000 -240 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 5M 22M 6M 6M 5M 26M 7M 6M 7M 29M 6M 38M 11M
otherExpenses 0 -567 000 -925 000 0 229 000 0 -1M -39 000 -11 000 -10000 -1M 0 0 -20M
operatingExpenses 14M 18M 84M 22M 22M 24M 128M 35M 37M 29M 107M 26M 97M 11M
costAndExpenses 14M 19M 85M 22M 22M 24M 130M 35M 37M 29M 108M 26M 97M 31M
interestIncome 133 000 233 000 3M 692 000 900 000 1M 6M 2M 1M 1M 2M 370 000 350 000 100 000
interestExpense 0 0 0 0 0 0 0 0 0 -1M 0 370 000 3000 1M
depreciationAndAmortization 56 000 115 000 925 000 228 000 229 000 240 000 1M 270 000 290 000 293 000 1M 700 000 1M 1M
ebitda -16M -19M -73M -11M -22M -24M -122M -35M -37M -29M -105M -25M -94M -33M
ebitdaratio 0 0 -1.004 0 0 0 0 0 0
operatingIncome -14M -19M -74M -11M -22M -24M -130M -35M -37M -29M -108M -26M -96M -30M
operatingIncomeRatio 0 0 -1.025 0 0 0 0 0 0
totalOtherIncomeExpensesNet -2M -64 000 4M 684 000 900 000 1M 6M -39 000 -11 000 1M 2M 400 000 1M -6M
incomeBeforeTax -16M -19M -70M -11M -21M -23M -123M -33M -36M -27M -106M -26M -95M -36M
incomeBeforeTaxRatio 0 0 -0.962 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 196 724 0 -2M -1M -1M 0 -370 000 0 0
netIncome -16M -19M -70M -11M -21M -23M -123M -33M -36M -26M -105M -25M -95M -36M
netIncomeRatio 0 0 -0.962 0 0 0 0 0 0
eps -0.27 -0.32 -1.44 -0.22 -0.44 -0.48 -2.58 -0.7 -0.75 -0.55 -2.74 -0.68 -2.76 -1.06
epsdiluted -0.27 -0.32 -0.22 -0.44 -0.48 -0.7 -0.75 -0.55 -0.68
weightedAverageShsOut 59M 59M 49M 48M 48M 48M 48M 48M 48M 48M 39M 38M 35M 34M
weightedAverageShsOutDil 59M 59M 49M 48M 48M 48M 48M 48M 48M 48M 39M 38M 35M 34M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-03-26 2023-03-23 2022-02-28 2021-03-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 3M 6M 2M 347 000 -1M
ebit -74M -123M -106M -95M -34M
nonOperatingIncomeExcludingInterest 0 -6M -2M -1M 4M
netIncomeFromContinuingOperations -70M -123M -106M -95M -36M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 1M 0 0
netIncomeDeductions 0 0 1M 0 0
bottomLineNetIncome -70M -123M -106M -95M -36M
epsDiluted -1.44 -2.58 -2.74 -2.76 -1.06

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2023-11-07 2023-08-01 2023-05-11 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2025-03-27 17:44:56 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23 2022-02-28 16:25:51 2021-03-24 17:28:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 8M 18M 49M 57M 62M 81M 111M 141M 169M 193M 216M 178M 245M 239M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 8M 18M 49M 57M 62M 81M 111M 141M 169M 193M 216M 178M 245M 239M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 1M 2M 447 000 4M 5M 6M 320 000 6M 687 000 469 000 539 000 519 000 2M 72 000
totalCurrentAssets 10M 21M 51M 61M 66M 86M 116M 141M 175M 200M 220M 183M 247M 241M
propertyPlantEquipmentNet 6M 6M 1M 0 2M 3M 3M 4M 4M 5M 5M 6M 7M 4M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 163 000 163 000 0 2M 0 154 000 154 000 6M 154 000 154 000 154 000 154 000 154 000 154 000
totalNonCurrentAssets 6M 7M 1M 2M 2M 3M 3M 10M 4M 5M 5M 6M 7M 4M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 16M 27M 52M 62M 69M 89M 120M 151M 180M 205M 226M 189M 254M 245M
accountPayables 0 5M 2M 0 1M 3M 4M 6M 3M 8M 4M 4M 1M 2M
shortTermDebt 1M 805 000 0 1M 3M 2M 0 2M 2M 2M 0 1M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 -6M -3M 0 0 0 0 20M
otherCurrentLiabilities 17M 11M 12M 18M 13M 14M 19M 34M 32M 17M 14M 19M 0 3M
totalCurrentLiabilities 18M 17M 15M 19M 17M 19M 28M 36M 34M 26M 23M 24M 20M 32M
longTermDebt 5M 5M 0 0 0 415 000 0 1M 2M 2M 0 3M 0 682 000
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 24M 22M 24M 20M 20M 20M 20M 20M 20M 20M 20M 17M 20M 2M
totalNonCurrentLiabilities 29M 27M 24M 20M 20M 20M 21M 21M 21M 22M 22M 23M 24M 3M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 6M 836 000 1M 2M 415 000 2M 3M 3M 4M 4M 4M 5M 0
totalLiabilities 47M 44M 38M 39M 37M 39M 49M 57M 55M 48M 45M 46M 44M 35M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 6000 6000 6000 5000 5000 5000 5000 5000 5000 5000 5000 4000 4000 3000
retainedEarnings -536M -520M -486M -471M -461M -439M -416M -389M -356M -320M -293M -265M -186M -91M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 -0 0
othertotalStockholdersEquity 505M 503M 494M 492M 489M 484M 481M 477M 408M
totalStockholdersEquity -31M -17M 14M 23M 31M 50M 71M 95M 125M 156M 180M 143M 211M 210M
totalEquity -31M -17M 14M 23M 31M 50M 71M 95M 125M 156M 180M 143M 211M 210M
totalLiabilitiesAndStockholdersEquity 16M 27M 62M 69M 89M 151M 180M 205M 189M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 16M 27M 52M 62M 69M 89M 120M 151M 180M 205M 226M 189M 254M 245M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 6M 6M 836 000 1M 2M 2M 2M 3M 3M 4M 4M 4M 5M 682 000
netDebt -2M -12M -48M -55M -60M -79M -109M -138M -165M -189M -212M -174M -240M -238M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-03-26 2023-03-23 2022-02-28 2021-03-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 2M 5M 4M 502 000 2M
totalPayables 2M 4M 4M 1M 2M
otherPayables 0 0 0 0 0
accruedExpenses 0 4M 3M 17M 7M
capitalLeaseObligationsCurrent 836 000 2M 2M 1M 0
capitalLeaseObligationsNonCurrent 0 836 000 2M 4M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 500M 487M 473M 397M 301M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2023-11-07 2023-08-01 2023-05-11 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2025-03-27 17:44:56 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23 2022-02-28 16:25:51 2021-03-24 17:28:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -16M -19M -70M -11M -21M -23M -123M -33M -36M -27M -106M -26M -95M -36M
depreciationAndAmortization 56 000 115 000 925 000 228 000 229 000 240 000 1M 270 000 290 000 293 000 1M 300 000 1M 1M
deferredIncomeTax 0 0 0 0 0 0 0 -30M -32M 0 0 0 -686 000 4M
stockBasedCompensation 0 0 9M 2M 2M 2M 14M 4M 4M 4M 15M 4M 25M 3M
changeInWorkingCapital 1M 3M -11M 11M -846 000 -10M 5M 2M 8M 899 000 287 000 -2M 7M -2M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 421 000 -13M 640 000 -2M -9M 5M 2M 7M 3M 3M -2M 8M -2M
otherWorkingCapital 1M 2M 2M 10M 1M -1M -604 000 235 000 269 000 -2M -3M -422 000 -568 000 -838 000
otherNonCashItems 4M 2M -807 000 -8M 5M 12M 2000 30M 32M 0 13 000 0 3000 -6M
netCashProvidedByOperatingActivities -10M -14M -72M -5M -19M -31M -104M -27M -24M -23M -90M -24M -62M -36M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -98 000 -25 000 -15 000 -50 000 -268 000 -58 000 -924 000 -590 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 -19 000
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 -25 000 -15 000 -50 000 -58 000
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 47 000 -244 000 244 000 0 27 000 54 000 0 0
commonStockRepurchased -6000 0 0 13 244 000 -13 0 14 000 173 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 -5000 -14 000 225 000 -13 000 -82 000 -112 000 -116 000 -96 000
netCashUsedProvidedByFinancingActivities -6000 42 000 -14 000 225 000 -13 000 -41 000 115 000 -116 000 -96 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 -2M -8M 0 0 0 0 0
netChangeInCash -10M -14M -62M -5M -19M -31M -104M -27M -24M -23M -29M -24M 6M 235M
cashAtEndOfPeriod 8M 18M 49M 57M 62M 81M 111M 141M 169M 193M 216M 178M 245M 239M
cashAtBeginningOfPeriod 18M 32M 111M 62M 81M 111M 216M 169M 193M 216M 245M 202M 239M 4M
operatingCashFlow -10M -14M -72M -5M -19M -31M -104M -27M -24M -23M -90M -24M -62M -36M
capitalExpenditure 0 14M 0 0 0 0 -98 000 -25 000 -15 000 -50 000 -268 000 -58 000 -924 000 -590 000
freeCashFlow -10M 0 -72M -5M -19M -31M -104M -27M -24M -23M -91M -24M -63M -37M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-03-26 2023-03-23 2022-02-28 2021-03-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 3000 0 19 000
netCashProvidedByInvestingActivities 0 -98 000 -265 000 -924 000 -590 000
netDebtIssuance 0 0 0 0 3M
longTermNetDebtIssuance 0 0 0 0 3M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 9M 336 000 62M 71M 268M
netCommonStockIssuance 9M 336 000 62M 71M 200M
commonStockIssuance 9M 336 000 62M 71M 200M
netPreferredStockIssuance 0 0 0 429 000 68M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 296 000 -259 000 -469 000 -2M -19 000
netCashProvidedByFinancingActivities 10M 77 000 61M 70M 272M
incomeTaxesPaid 0 6000 67 000 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-13 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-03-27 ET (fiscal 2024 q4)
2024 q3
2024-11-09 ET (fiscal 2024 q3)
2024 q2
2024-08-11 ET (fiscal 2024 q2)
2024 q1
2024-05-14 ET (fiscal 2024 q1)
2023 q4
2024-03-26 ET (fiscal 2023 q4)
2023 q3
2023-11-12 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-23 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-13 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-13 17:00 ET
BioAtla, Inc. reported for 2025 q3
SEC form 8
2025-11-13 16:06 ET
BioAtla, Inc. reported for 2025 q3
SEC form 8
2025-11-13 16:06 ET
BioAtla, Inc. published news for 2025 q3
SEC form 10
2025-08-07 21:01 ET
BioAtla, Inc. reported for 2025 q2
SEC form 8
2025-08-07 20:06 ET
BioAtla, Inc. published news for 2025 q2
SEC form 8
2025-08-07 20:06 ET
BioAtla, Inc. reported for 2025 q2
SEC form 10
2025-05-06 21:01 ET
BioAtla, Inc. reported for 2025 q1
SEC form 8
2025-05-06 20:01 ET
BioAtla, Inc. published news for 2025 q1
SEC form 8
2025-05-06 20:01 ET
BioAtla, Inc. reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
BioAtla, Inc. reported for 2025 q1
SEC form 10
2025-03-28 00:00 ET
BioAtla, Inc. reported for 2024 q4
SEC form 10
2025-03-27 21:44 ET
BioAtla, Inc. reported for 2024 q4
SEC form 8
2025-03-27 16:09 ET
BioAtla, Inc. reported for 2024 q4
SEC form 8
2025-03-27 16:09 ET
BioAtla, Inc. published news for 2024 q4
SEC form 10
2024-11-07 17:05 ET
BioAtla, Inc. reported for 2024 q3
SEC form 8
2024-11-07 16:05 ET
BioAtla, Inc. published news for 2024 q3
SEC form 8
2024-11-07 16:05 ET
BioAtla, Inc. reported for 2024 q3
SEC form 10
2024-08-08 17:01 ET
BioAtla, Inc. reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
BioAtla, Inc. reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
BioAtla, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
BioAtla, Inc. reported for 2024 q2
SEC form 10
2024-05-14 17:01 ET
BioAtla, Inc. reported for 2024 q1
SEC form 8
2024-05-14 16:05 ET
BioAtla, Inc. reported for 2024 q1
SEC form 8
2024-05-14 16:05 ET
BioAtla, Inc. published news for 2024 q1
SEC form 10
2024-05-14 00:00 ET
BioAtla, Inc. reported for 2024 q1
SEC form 10
2024-03-26 17:05 ET
BioAtla, Inc. reported for 2023 q4
SEC form 8
2024-03-26 16:01 ET
BioAtla, Inc. published news for 2023 q4
SEC form 8
2024-03-26 16:01 ET
BioAtla, Inc. reported for 2023 q4
SEC form 10
2024-03-26 00:00 ET
BioAtla, Inc. reported for 2023 q4
SEC form 10
2023-11-07 17:05 ET
BioAtla, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:02 ET
BioAtla, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
BioAtla, Inc. reported for 2023 q3
SEC form 10
2023-08-01 17:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 6
2023-08-01 16:02 ET
BioAtla, Inc. reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 6
2023-06-14 17:01 ET
BioAtla, Inc. published news for 2023 q1
SEC form 10
2023-05-11 17:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:06 ET
BioAtla, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 6
2023-04-24 17:12 ET
BioAtla, Inc. published news for 2023 q1
SEC form 10
2023-03-23 17:06 ET
BioAtla, Inc. reported for 2022 q4
SEC form 6
2023-03-23 16:02 ET
BioAtla, Inc. reported for 2022 q4
SEC form 8
2023-03-23 00:00 ET
BioAtla, Inc. reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
BioAtla, Inc. reported for 2022 q4
SEC form 10
2022-11-04 00:00 ET
BioAtla, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
BioAtla, Inc. reported for 2022 q3
SEC form 8
2022-08-09 00:00 ET
BioAtla, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
BioAtla, Inc. reported for 2022 q2
SEC form 10
2022-05-05 00:00 ET
BioAtla, Inc. reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
BioAtla, Inc. reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
BioAtla, Inc. published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
BioAtla, Inc. published news for 2021 q3
SEC form 10
2021-08-13 00:00 ET
BioAtla, Inc. published news for 2021 q2
SEC form 10
2021-05-12 00:00 ET
BioAtla, Inc. published news for 2021 q1